Differences in the Management of Adolescents with Polycystic Ovary Syndrome across Pediatric Specialties

Auble, Bethany; Elder, Deborah A.; Gross, Andrea M.; Hillman, Jennifer B.

doi:10.1016/j.jpag.2013.03.007

Cited by 32 publications

(26 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment program should be symptomatic supportive treatment, with a core focus on reducing the androgen level. Adolescent PCOS would affect the adolescent psychology and physiological development, thus the appropriate treatment and life guidance would aid in the subsequent adult health state (25,26).…”

Section: Discussionmentioning

confidence: 99%

Bak Foong pills combined with metformin in the treatment of a polycystic ovarian syndrome rat model

Liu

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the treatment effects and associated mechanism of Bak Foong pills (BFPs) combined with metformin in the treatment of polycystic ovarian syndrome (PCOS). BFPs and/or metformin were administrated to treat the PCOS rats, and the weights and morphologies of the ovary, uterus and adrenal gland were measured. The levels of fasting blood glucose (FBG), serum testosterone (T), luteinizing hormone, fasting insulin (FIN) and insulin-like growth factor-1 were also measured, and the homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. The expression level of androgen receptor (AR) in the ovarian tissue, and the cytochrome P450 cholesterol side-chain cleavage enzyme (P450scc) mRNA levels in the ovary and adrenal tissues were detected. The levels of T, FIN, FBG and HOMA-IR in the combination group were significantly reduced; the wet weights of the ovary and the adrenal gland were decreased significantly, while that of the uterus was increased, and the histological morphology benignly recovered. The rats of each treatment group all experienced restored ovulation. The AR expression level in the treatment group was reduced, and the P450scc mRNA levels in the ovary and the adrenal gland of the combined treatment group were decreased. BFPs combined with metformin significantly affected PCOS, and the possible mechanism involved in the treatment may have been through the reduction of P450scc generation. BFPs may reduce the androgen levels, thus allowing the ovary to restore ovulation.

show abstract

Section: Discussionmentioning

confidence: 99%

Bak Foong pills combined with metformin in the treatment of a polycystic ovarian syndrome rat model

Liu

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…PCOS treatment presents clinical equipoise that is highlighted by the lack of consensus between guidelines around the world for the best treatment approach. [24][25][26] Therefore, we aimed to evaluate the effectiveness of metformin use versus OCP in adolescents aged 11 to 19 years with PCOS in improving menstrual cyclicity, clinical hyperandrogenism, and metabolic profile.…”

mentioning

confidence: 99%

Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Our study has relevant clinical implications in the identification of a subgroup of adolescents with PCOS who may benefit more from earlier intervention and modification of lifestyle, a recommendation often overlooked [15,52]. …”

Section: Discussionmentioning

confidence: 99%

“…This is all the more pertinent in adolescents because of the lack of uniformly accepted guidelines on diagnosis and management [6,15,16]. PCOS may be associated with insulin resistance, increasing risk of type 2 diabetes and impaired glucose tolerance independent of body weight [17,18,19,20].…”

Section: Introductionmentioning

confidence: 99%

Phenotypic Characterization of Polycystic Ovary Syndrome in Adolescents Based on Menstrual Irregularity

Javed

Kumar²,

Simmons

et al. 2015

Horm Res Paediatr

View full text Add to dashboard Cite

Objective: Polycystic ovary syndrome (PCOS) in adolescents is associated with adverse metabolic outcomes. The association of menstrual irregularity with metabolic risk among adolescents with PCOS was assessed. Method: A retrospective medical record review of 366 adolescents with PCOS aged 13-18 years was conducted, from which 265 girls newly diagnosed with PCOS were included and divided into those presenting with primary amenorrhea (PA), secondary amenorrhea (SA) and oligomenorrhea (OM). Androgen concentrations and markers of metabolic risk were compared among the groups. Results: Most subjects presented with OM (PA = 17, SA = 30 and OM = 218). Subjects with PA were younger than those with OM but not different from those with SA. Mean BMI was not different between groups. Total testosterone and insulin levels were higher in PA than SA and OM (p < 0.01 and 0.02, respectively). Fasting glucose was higher in PA than OM (p = 0.048) but not different from SA. Triglyceride levels were higher in PA than SA and OM (p < 0.001 each). More subjects with PA and SA had metabolic syndrome (52%) than those with OM (29.1%) (p = 0.027). The differences in triglycerides and glucose persisted despite BMI adjustment in multivariate regression models. Conclusion: Adolescents with PCOS presenting with PA are at risk of metabolic disease beyond expected based on BMI.

show abstract

Differences in the Management of Adolescents with Polycystic Ovary Syndrome across Pediatric Specialties

Cited by 32 publications

References 16 publications

Bak Foong pills combined with metformin in the treatment of a polycystic ovarian syndrome rat model

Bak Foong pills combined with metformin in the treatment of a polycystic ovarian syndrome rat model

Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis

Phenotypic Characterization of Polycystic Ovary Syndrome in Adolescents Based on Menstrual Irregularity

Contact Info

Product

Resources

About